Nathan L. Mata, chief scientific officer of Belite Bio (BLTE), has been a consistent seller of company stock in recent weeks, with a pronounced sell-side bias across his Form 4 filings. Over his 103 reported transactions, all concentrated in BLTE, Mata has executed zero open-market purchases and accumulated roughly $2.66 million in total sales. The most recent activity, spanning May 1 through May 7, 2026, shows 25 separate open-market sale transactions, with individual values ranging from a modest $463.83 to a significant $65,725.18. This cluster of sales, executed nearly daily during the period, points to a deliberate and ongoing reduction of his position rather than a one-off liquidity event.
The pattern is unambiguous: Mata's trading history contains no buys, no option exercises, and no acquisitions of any kind. Every transaction in the dataset is a sale, and the recent batch alone accounts for over $575,000 in proceeds. The largest single-day activity occurred on May 7, when four sales totaled roughly $102,000, while May 5 saw six sales worth approximately $155,500. The consistent daily cadence and the absence of any counterbalancing purchases suggest a sustained disposition strategy, though the filings do not indicate whether these sales are part of a pre-arranged 10b5-1 plan or discretionary decisions. For shareholders tracking insider behavior, the signal is clear: Mata has been a net and persistent seller of BLTE stock, with no recent indication of accumulation.
AI-assisted summary